BridgeBio Pharma Inc logo

BridgeBio Pharma Inc

NAS:BBIO (USA)  
$ 25.41 +0.13 (+0.52%) 11:08 PM EST
At Loss
Volume:
3.60M
Avg Vol (2M):
2.08M
Trade In:
Volume:
3.60M
At Loss
Avg Vol (2M):
2.08M

Business Description

Description
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.
Name Current Vs Industry Vs History
Cash-To-Debt 0.3
Equity-to-Asset -1.24
Debt-to-Equity -1.65
Debt-to-EBITDA -3.8
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -3.4
Distress
Grey
Safe
Beneish M-Score 5.79
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 49.45
9-Day RSI 44.14
14-Day RSI 43.64
6-1 Month Momentum % -33.46
12-1 Month Momentum % 54.47

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 5.54
Quick Ratio 5.54
Cash Ratio 3.67
Days Payable 848.21

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -12.5
Shareholder Yield % -13.19